Recommendations for tapering/discontinuing DMARDs (Table 5) Because of the moderate-to-high risk for flare and the potential for irreversible long-term damage associated with stopping all DMARDs, the following recommendations presume that patients maintain a therapeutic dose of at least 1 DMARD. In addition, the recommendations specify that patients be at target (low disease activity or remission) for at least 6 months prior to tapering. Patients in remission for <6 months should not routinely